Evidence map›Paper›PMID 31835974›Full record

ArticleJournal of medical economics2020

Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models.

T A Rautenberg, G George, M B Bwana, M S Moosa, S Pillay, S M McCluskey, I Aturinda, K Ard, W Muyindike, P Moodley and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical economics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02787499 (Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02787499 nacompletednot on this map

Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa

TypeinterventionalSponsorMassachusetts General HospitalRan2016 to 2020Enrolled840ConditionsHIV, AIDSArmsHIV-1 RNA Resistance Testing
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

T A RautenbergDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
G GeorgeDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
M B BwanaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
M S MoosaDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
S PillayDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
S M McCluskeyDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
I AturindaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
K ArdDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
W MuyindikeFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
P MoodleyDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
J BrijkumarDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
B A JohnsonDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA.
R T GandhiDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
H SunpathDivision of Medicine, University of KwaZulu-Natal, Durban, South Africa.
V C MarconiDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
M J SiednerDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3506-842X

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trialR01AI124718 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MUYINDIKE, WINNIE, SIEDNER, MARK J · 2016 to 2020
$3.0M
Behavioral Aspects of Low-cost Medical Devices to Improve HIV CareK23MH099916 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI SIEDNER, MARK J · 2013 to 2017
$917k
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI124718NIMH NIH HHS K23 MH099916
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Models, EconomicAnti-Retroviral AgentsCD4-Positive T-LymphocytesCost-Benefit AnalysisDrug ResistanceHIV InfectionsHumansQuality of LifeTime FactorsViral LoadAnti-Retroviral AgentsComparative analysiscost effectiveness modelingeconomic evaluationhealth economics methodologyI10

Identifiers

PMID31835974
PMCPMC7105898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.